Cargando…

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

BACKGROUND: Targeted drugs have greatly improved the therapeutic outcome of non‐small cell lung cancer (NSCLC) patients compared with conventional chemotherapy, whereas about one‐third of patients are so far not suitable for targeted therapy due to lack of known driver oncogenes such as a mutated re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qianqian, Li, Jun, Zhu, Jing, Mao, Jiaqi, Duan, Chao, Liang, Xiao, Zhu, Lingyun, Zhu, Mengyan, Zhang, Zhihong, Lin, Fan, Guo, Renhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189421/ https://www.ncbi.nlm.nih.gov/pubmed/35692096 http://dx.doi.org/10.1002/ctm2.882

Ejemplares similares

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
por: Stolte, Björn, et al.
Publicado: (2018)

CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells
por: Geisinger, Jonathan M, et al.
Publicado: (2020)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
por: Wang, Shuhang, et al.
Publicado: (2020)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
por: Hou, Helei, et al.
Publicado: (2019)

Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications
por: Pini, Veronica, et al.
Publicado: (2022)

TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening
por: Álvarez, Miguel M., et al.
Publicado: (2022)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

CRISPR/Cas9 system and its applications in nervous system diseases
por: Jiang, Haibin, et al.
Publicado: (2023)

Comprehensive Analysis of CRISPR/Cas9-Mediated Mutagenesis in Arabidopsis thaliana by Genome-Wide Sequencing
por: Xu, Wenjie, et al.
Publicado: (2019)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

Evaluation of sgRNA Target Sites for CRISPR-Mediated Repression of TP53
por: Lawhorn, Ingrid E. B., et al.
Publicado: (2014)

Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation
por: Tanihara, Fuminori, et al.
Publicado: (2018)

In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region
por: Kohabir, Kavish A.V., et al.
Publicado: (2023)

PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner
por: Luo, Dehong, et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Correction: PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner
por: Luo, Dehong, et al.
Publicado: (2019)

CRISPR/Cas9-Mediated genomic knock out of tyrosine hydroxylase and yellow genes in cricket Gryllus bimaculatus
por: Bai, Yun, et al.
Publicado: (2023)

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
por: Liu, Yutao, et al.
Publicado: (2019)

A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53
por: Cao, Congcong, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Elimination of an unfavorable allele conferring pod shattering in an elite soybean cultivar by CRISPR/Cas9
por: Zhang, Zhihui, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use
por: Jiang, Long, et al.
Publicado: (2022)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Effect of CMB Carrying PTX and CRISPR/Cas9 on Endometrial Cancer Naked Mouse Model
por: Cai, Junhong, et al.
Publicado: (2022)

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
por: Gao, Qianqian, et al.
Publicado: (2019)

Structural insights into the inactivation of CRISPR-Cas systems by diverse anti-CRISPR proteins
por: Zhu, Yuwei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fmr908hdbknp4jau1ensmvd4li